Danaher Co. (NYSE:DHR) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC cut its stake in shares of Danaher Co. (NYSE:DHR) by 12.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 13,727 shares of the conglomerate’s stock after selling 2,023 shares during the period. Avior Wealth Management LLC’s holdings in Danaher were worth $3,151,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher during the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth about $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DHR. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. TD Cowen increased their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 0.6 %

Shares of Danaher stock opened at $245.73 on Friday. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The business’s 50 day simple moving average is $234.90 and its 200-day simple moving average is $253.47. The stock has a market capitalization of $177.49 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.